Advertisement
Surgical Pathology Clinics

How New Developments Impact Diagnosis in Existing Renal Neoplasms

Published:October 12, 2022DOI:https://doi.org/10.1016/j.path.2022.07.005

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Surgical Pathology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • MacLennan G.T.
        • Cheng L.
        Five decades of urologic pathology: the accelerating expansion of knowledge in renal cell neoplasia.
        Hum Pathol. 2020; 95: 24-45
        • Siegel R.L.
        • Miller K.D.
        • Fuchs H.E.
        • et al.
        Cancer statistics, 2021.
        CA Cancer J Clin. 2021; 71: 7-33
        • Leibovich B.C.
        • Lohse C.M.
        • Crispen P.L.
        • et al.
        Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma.
        J Urol. 2010; 183: 1309-1315
        • Kluger N.
        • Giraud S.
        • Coupier I.
        • et al.
        Birt-Hogg-Dube syndrome: clinical and genetic studies of 10 French families.
        Br J Dermatol. 2010; 162: 527-537
        • Akgul M.
        • Williamson S.R.
        Immunohistochemistry for the diagnosis of renal epithelial neoplasms.
        Semin Diagn Pathol. 2022; 39: 1-16
        • Williamson S.R.
        • Kum J.B.
        • Goheen M.P.
        • et al.
        Clear cell renal cell carcinoma with a syncytial-type multinucleated giant tumor cell component: implications for differential diagnosis.
        Hum Pathol. 2014; 45: 735-744
        • Alaghehbandan R.
        • Limani R.
        • Ali L.
        • et al.
        Clear cell renal cell carcinoma with prominent microvascular hyperplasia: Morphologic, immunohistochemical and molecular-genetic analysis of 7 sporadic cases.
        Ann Diagn Pathol. 2022; 56: 151871
        • Ross H.
        • Martignoni G.
        • Argani P.
        Renal cell carcinoma with clear cell and papillary features.
        Arch Pathol Lab Med. 2012; 136: 391-399
        • Hes O.
        • Benakova K.
        • Vanecek T.
        • et al.
        Clear cell type of renal cell carcinoma with numerous hyaline globules: a diagnostic pitfall.
        Pathol Int. 2005; 55: 150-154
        • Gournay M.
        • Dugay F.
        • Belaud-Rotureau M.A.
        • et al.
        Renal cell carcinoma with leiomyomatous stroma in tuberous sclerosis complex: a distinct entity.
        Virchows Arch. 2021; 478: 793-799
        • Hes O.
        • Compérat E.M.
        • Rioux-Leclercq N.
        Clear cell papillary renal cell carcinoma, renal angiomyoadenomatous tumor, and renal cell carcinoma with leiomyomatous stroma relationship of 3 types of renal tumors: a review.
        Ann Diagn Pathol. 2016; 21: 59-64
        • Shah R.B.
        • Stohr B.A.
        • Tu Z.J.
        • et al.
        Renal cell carcinoma with leiomyomatous stroma" harbor somatic mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): clinicopathologic and molecular characterization of 18 sporadic tumors supports a distinct entity.
        Am J Surg Pathol. 2020; 44: 571-581
        • Ricketts C.J.
        • De Cubas A.A.
        • Fan H.
        • et al.
        The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma.
        Cell Rep. 2018; 23: 313-326.e315
        • Jonasch E.
        • Walker C.L.
        • Rathmell W.K.
        Clear cell renal cell carcinoma ontogeny and mechanisms of lethality.
        Nat Rev Nephrol. 2021; 17: 245-261
        • Clark D.J.
        • Dhanasekaran S.M.
        • Petralia F.
        • et al.
        Integrated proteogenomic characterization of clear cell renal cell carcinoma.
        Cell. 2019; 179: 964-983 e931
        • Latif F.
        • Tory K.
        • Gnarra J.
        • et al.
        Identification of the von Hippel-Lindau disease tumor suppressor gene.
        Science. 1993; 260: 1317-1320
      1. Comprehensive molecular characterization of clear cell renal cell carcinoma.
        Nature. 2013; 499: 43-49
        • Gossage L.
        • Eisen T.
        • Maher E.R.V.H.L.
        the story of a tumour suppressor gene.
        Nat Rev Cancer. 2015; 15: 55-64
        • Bui T.O.
        • Dao V.T.
        • Nguyen V.T.
        • et al.
        Genomics of clear-cell renal cell carcinoma: a systematic review and meta-analysis.
        Eur Urol. 2022; 81: 349-361
        • Maxwell P.H.
        • Dachs G.U.
        • Gleadle J.M.
        • et al.
        Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth.
        Proc Natl Acad Sci U S A. 1997; 94: 8104-8109
        • Weidemann A.
        • Johnson R.S.
        Biology of HIF-1α.
        Cell Death Differ. 2008; 15: 621-627
        • Linehan W.M.
        • Ricketts C.J.
        The cancer genome atlas of renal cell carcinoma: findings and clinical implications.
        Nat Rev Urol. 2019; 16: 539-552
        • Turajlic S.
        • Xu H.
        • Litchfield K.
        • et al.
        Deterministic evolutionary trajectories influence primary tumor growth: TRACERx renal.
        Cell. 2018; 173: 595-610.e511
        • Gallan A.J.
        • Parilla M.
        • Segal J.
        • et al.
        BAP1-mutated clear cell renal cell carcinoma.
        Am J Clin Pathol. 2021; 155: 718-728
        • Brunelli M.
        • Eble J.N.
        • Zhang S.
        • et al.
        Eosinophilic and classic chromophobe renal cell carcinomas have similar frequent losses of multiple chromosomes from among chromosomes 1, 2, 6, 10, and 17, and this pattern of genetic abnormality is not present in renal oncocytoma.
        Mod Pathol. 2005; 18: 161-169
        • Michal M.
        • Hes O.
        • Svec A.
        • et al.
        Pigmented microcystic chromophobe cell carcinoma: a unique variant of renal cell carcinoma.
        Ann Diagn Pathol. 1998; 2: 149-153
        • Michalova K.
        • Tretiakova M.
        • Pivovarcikova K.
        • et al.
        Expanding the morphologic spectrum of chromophobe renal cell carcinoma: a study of 8 cases with papillary architecture.
        Ann Diagn Pathol. 2020; 44: 151448
        • Delahunt B.
        • Cheville J.C.
        • Martignoni G.
        • et al.
        The international society of urological pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters.
        Am J Surg Pathol. 2013; 37: 1490-1504
        • Delahunt B.
        • Sika-Paotonu D.
        • Bethwaite P.B.
        • et al.
        Fuhrman grading is not appropriate for chromophobe renal cell carcinoma.
        Am J Surg Pathol. 2007; 31: 957-960
        • Volpe A.
        • Novara G.
        • Antonelli A.
        • et al.
        Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
        BJU Int. 2012; 110: 76-83
        • Avulova S.
        • Cheville J.C.
        • Lohse C.M.
        • et al.
        Grading Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis.
        Eur Urol. 2021; 79: 225-231
        • Paner G.P.
        • Amin M.B.
        • Alvarado-Cabrero I.
        • et al.
        A novel tumor grading scheme for chromophobe renal cell carcinoma: prognostic utility and comparison with Fuhrman nuclear grade.
        Am J Surg Pathol. 2010; 34: 1233-1240
        • Ohashi R.
        • Martignoni G.
        • Hartmann A.
        • et al.
        Multi-institutional re-evaluation of prognostic factors in chromophobe renal cell carcinoma: proposal of a novel two-tiered grading scheme.
        Virchows Arch. 2020; 476: 409-418
        • Delahunt B.
        • Samaratunga H.
        • Egevad L.
        Re: Svetlana Avulova, John C. Cheville, Christine M. Lohse, et al. Grading of chromophobe renal cell carcinoma: evidence for a four-tiered classification incorporating coagulative tumor necrosis. Eur Urol 2021;79:225-231: Should chromophobe renal cell carcinoma be graded?.
        Eur Urol. 2021; 79: e141-e142
        • Lopez-Beltran A.
        • Montironi R.
        • Cimadamore A.
        • et al.
        Grading of chromophobe renal cell carcinoma: do we need it?.
        Eur Urol. 2021; 79: 232-233
        • Wobker S.E.
        • Williamson S.R.
        Modern pathologic diagnosis of renal oncocytoma.
        J Kidney Cancer VHL. 2017; 4: 1-12
        • Casuscelli J.
        • Weinhold N.
        • Gundem G.
        • et al.
        Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma.
        JCI Insight. 2017; 2
        • Moch H.
        • Cubilla A.L.
        • Humphrey P.A.
        • et al.
        The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours.
        Eur Urol. 2016; 70: 93-105
        • Tickoo S.K.
        • dePeralta-Venturina M.N.
        • Harik L.R.
        • et al.
        Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia.
        Am J Surg Pathol. 2006; 30: 141-153
        • Williamson S.R.
        Clear cell papillary renal cell carcinoma: an update after 15 years.
        Pathology. 2021; 53: 109-119
        • Aron M.
        • Chang E.
        • Herrera L.
        • et al.
        Clear cell-papillary renal cell carcinoma of the kidney not associated with end-stage renal disease: clinicopathologic correlation with expanded immunophenotypic and molecular characterization of a large cohort with emphasis on relationship with renal angiomyoadenomatous tumor.
        Am J Surg Pathol. 2015; 39: 873-888
        • Zhao J.
        • Eyzaguirre E.
        Clear cell papillary renal cell carcinoma.
        Arch Pathol Lab Med. 2019; 143: 1154-1158
        • Aydin H.
        • Chen L.
        • Cheng L.
        • et al.
        Clear cell tubulopapillary renal cell carcinoma: a study of 36 distinctive low-grade epithelial tumors of the kidney.
        Am J Surg Pathol. 2010; 34: 1608-1621
        • Lawrie C.H.
        • Larrea E.
        • Larrinaga G.
        • et al.
        Targeted next-generation sequencing and non-coding RNA expression analysis of clear cell papillary renal cell carcinoma suggests distinct pathological mechanisms from other renal tumour subtypes.
        J Pathol. 2014; 232: 32-42
        • Massari F.
        • Ciccarese C.
        • Hes O.
        • et al.
        The tumor entity denominated "clear cell-papillary renal cell carcinoma" according to the WHO 2016 new classification, have the clinical characters of a renal cell adenoma as does harbor a benign outcome.
        Pathol Oncol Res. 2018; 24: 447-456
        • Morlote D.M.
        • Harada S.
        • Batista D.
        • et al.
        Clear cell papillary renal cell carcinoma: molecular profile and virtual karyotype.
        Hum Pathol. 2019; 91: 52-60
        • Steward J.E.
        • Kern S.Q.
        • Cheng L.
        • et al.
        Clear cell papillary renal cell carcinoma: Characteristics and survival outcomes from a large single institutional series.
        Urol Oncol. 2021; 39: 370.e321-370.e325
        • Cheville J.
        • Helenon O.
        • Hes O.
        • et al.
        WHO classification of tumours online: urinary and male genital tumours: clear cell papillary renal cell tumor.
        (Available at:) (Accessed March 15, 2022)
        • Gandhi J.S.
        • Malik F.
        • Amin M.B.
        • et al.
        MiT family translocation renal cell carcinomas: a 15th anniversary update.
        Histol Histopathol. 2020; 35: 125-136
        • de Jong B.
        • Molenaar I.M.
        • Leeuw J.A.
        • et al.
        Cytogenetics of a renal adenocarcinoma in a 2-year-old child.
        Cancer Genet Cytogenet. 1986; 21: 165-169
        • Caliò A.
        • Harada S.
        • Brunelli M.
        • et al.
        TFEB rearranged renal cell carcinoma. A clinicopathologic and molecular study of 13 cases. Tumors harboring MALAT1-TFEB, ACTB-TFEB, and the novel NEAT1-TFEB translocations constantly express PDL1.
        Mod Pathol. 2021; 34: 842-850
        • Xia Q.Y.
        • Wang X.T.
        • Ye S.B.
        • et al.
        Novel gene fusion of PRCC-MITF defines a new member of MiT family translocation renal cell carcinoma: clinicopathological analysis and detection of the gene fusion by RNA sequencing and FISH.
        Histopathology. 2018; 72: 786-794
        • Lang M.
        • Vocke C.D.
        • Ricketts C.J.
        • et al.
        Clinical and Molecular Characterization of Microphthalmia-associated Transcription Factor (MITF)-related Renal Cell Carcinoma.
        Urology. 2021; 149: 89-97
        • Bakouny Z.
        • Sadagopan A.
        • Ravi P.
        • et al.
        Integrative clinical and molecular characterization of translocation renal cell carcinoma.
        Cell Rep. 2022; 38: 110190
        • Akgul M.
        • Saeed O.
        • Levy D.
        • et al.
        Morphologic and immunohistochemical characteristics of fluorescent in situ hybridization confirmed TFE3-gene fusion associated renal cell carcinoma: a single institutional cohort.
        Am J Surg Pathol. 2020; 44: 1450-1458
        • Skala S.L.
        • Xiao H.
        • Udager A.M.
        • et al.
        Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays.
        Mod Pathol. 2018; 31: 179-197
        • Kato I.
        • Furuya M.
        • Baba M.
        • et al.
        RBM10-TFE3 renal cell carcinoma characterised by paracentric inversion with consistent closely split signals in break-apart fluorescence in-situ hybridisation: study of 10 cases and a literature review.
        Histopathology. 2019; 75: 254-265
        • Kuthi L.
        • Somorácz Á.
        • Micsik T.
        • et al.
        Clinicopathological findings on 28 Cases with XP11.2 renal cell carcinoma.
        Pathol Oncol Res. 2020; 26: 2123-2133
        • Argani P.
        • Zhong M.
        • Reuter V.E.
        • et al.
        TFE3-fusion variant analysis defines specific clinicopathologic associations among Xp11 translocation cancers.
        Am J Surg Pathol. 2016; 40: 723-737
        • Classe M.
        • Malouf G.G.
        • Su X.
        • et al.
        Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas.
        Histopathology. 2017; 70: 1089-1097
        • Zhong M.
        • De Angelo P.
        • Osborne L.
        • et al.
        Dual-color, break-apart FISH assay on paraffin-embedded tissues as an adjunct to diagnosis of Xp11 translocation renal cell carcinoma and alveolar soft part sarcoma.
        Am J Surg Pathol. 2010; 34: 757-766
        • Sidhar S.K.
        • Clark J.
        • Gill S.
        • et al.
        The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene.
        Hum Mol Genet. 1996; 5: 1333-1338
        • Argani P.
        • Antonescu C.R.
        • Illei P.B.
        • et al.
        Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents.
        Am J Pathol. 2001; 159: 179-192
        • Clark J.
        • Lu Y.J.
        • Sidhar S.K.
        • et al.
        Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma.
        Oncogene. 1997; 15: 2233-2239
        • Argani P.
        • Zhang L.
        • Reuter V.E.
        • et al.
        RBM10-TFE3 renal cell carcinoma: a potential diagnostic pitfall due to cryptic intrachromosomal Xp11.2 inversion resulting in false-negative TFE3 FISH.
        Am J Surg Pathol. 2017; 41: 655-662
        • Antic T.
        • Taxy J.B.
        • Alikhan M.
        • et al.
        Melanotic translocation renal cell carcinoma with a novel ARID1B-TFE3 gene fusion.
        Am J Surg Pathol. 2017; 41: 1576-1580
        • Fukuda H.
        • Kato I.
        • Furuya M.
        • et al.
        A novel partner of TFE3 in the Xp11 translocation renal cell carcinoma: clinicopathological analyses and detection of EWSR1-TFE3 fusion.
        Virchows Arch. 2019; 474: 389-393
        • Pei J.
        • Cooper H.
        • Flieder D.B.
        • et al.
        NEAT1-TFE3 and KAT6A-TFE3 renal cell carcinomas, new members of MiT family translocation renal cell carcinoma.
        Mod Pathol. 2019; 32: 710-716
        • Ye H.
        • Qin S.
        • Li N.
        • et al.
        A Rare Partner of TFE3 in the Xp11 Translocation Renal Cell Carcinoma: Clinicopathological Analyses and Detection of MED15-TFE3 Fusion.
        Biomed Res Int. 2019; 2019: 5974089
        • Akgul M.
        • Williamson S.R.
        • Ertoy D.
        • et al.
        Diagnostic approach in TFE3-rearranged renal cell carcinoma: a multi-institutional international survey.
        J Clin Pathol. 2021; 74: 291-299
        • Sharain R.F.
        • Gown A.M.
        • Greipp P.T.
        • et al.
        Immunohistochemistry for TFE3 lacks specificity and sensitivity in the diagnosis of TFE3-rearranged neoplasms: a comparative, 2-laboratory study.
        Hum Pathol. 2019; 87: 65-74
        • Akgul M.
        • Al-Obaidy K.I.
        • Cheng L.
        • et al.
        Low-grade oncocytic tumour expands the spectrum of renal oncocytic tumours and deserves separate classification: a review of 23 cases from a single tertiary institute.
        J Clin Pathol. 2021; (online ahead of print)
        • Gupta S.
        • Rowsey R.A.
        • Cheville J.C.
        • et al.
        Morphologic overlap between low-grade oncocytic tumor and eosinophilic variant of chromophobe renal cell carcinoma.
        Hum Pathol. 2022; 119: 114-116
        • Kravtsov O.
        • Gupta S.
        • Cheville J.C.
        • et al.
        Low-grade oncocytic tumor of kidney (CK7-Positive, CD117-Negative): incidence in a single institutional experience with clinicopathological and molecular characteristics.
        Hum Pathol. 2021; 114: 9-18
        • Morini A.
        • Drossart T.
        • Timsit M.O.
        • et al.
        Low-grade oncocytic renal tumor (LOT): mutations in mTOR pathway genes and low expression of FOXI1.
        Mod Pathol. 2022; 35: 352-360
        • Siadat F.
        • Trpkov K.
        ESC, ALK, HOT and LOT: three letter acronyms of emerging renal entities knocking on the door of the WHO classification.
        Cancers (Basel). 2020; 12: 168
        • Trpkov K.
        • Williamson S.R.
        • Gao Y.
        • et al.
        Low-grade oncocytic tumour of kidney (CD117-negative, cytokeratin 7-positive): a distinct entity?.
        Histopathology. 2019; 75: 174-184
        • Trpkov K.
        • Williamson S.R.
        • Gill A.J.
        • et al.
        Novel, emerging and provisional renal entities: the genitourinary pathology society (GUPS) update on renal neoplasia.
        Mod Pathol. 2021; 34: 1167-1184
        • Zhang H.Z.
        • Xia Q.Y.
        • Wang S.Y.
        • et al.
        Low-grade oncocytic tumor of kidney harboring TSC/MTOR mutation: clinicopathologic, immunohistochemical and molecular characteristics support a distinct entity.
        Virchows Arch. 2022; 480: 999-1008
        • Farcas M.
        • Gatalica Z.
        • Trpkov K.
        • et al.
        Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases.
        Mod Pathol. 2022; 35: 344-351
        • He H.
        • Trpkov K.
        • Martinek P.
        • et al.
        High-grade oncocytic renal tumor": morphologic, immunohistochemical, and molecular genetic study of 14 cases.
        Virchows Arch. 2018; 473: 725-738
        • Kapur P.
        • Gao M.
        • Zhong H.
        • et al.
        Eosinophilic vacuolated tumor of the kidney: a review of evolving concepts in this novel subtype with additional insights from a case with MTOR Mutation and concomitant chromosome 1 loss.
        Adv Anat Pathol. 2021; 28: 251-257
        • Aldera A.P.
        • Hes O.
        Eosinophilic solid and cystic renal cell carcinoma with melanin pigment-expanding the morphological spectrum.
        Int J Surg Pathol. 2022; 30: 295-299
        • McKenney J.K.
        • Przybycin C.G.
        • Trpkov K.
        • et al.
        Eosinophilic solid and cystic renal cell carcinomas have metastatic potential.
        Histopathology. 2018; 72: 1066-1067
        • Mehra R.
        • Vats P.
        • Cao X.
        • et al.
        Somatic Bi-allelic loss of TSC Genes in eosinophilic solid and cystic renal cell carcinoma.
        Eur Urol. 2018; 74: 483-486
        • Munari E.
        • Settanni G.
        • Caliò A.
        • et al.
        TSC loss is a clonal event in eosinophilic solid and cystic renal cell carcinoma: a multiregional tumor sampling study.
        Mod Pathol. 2022; 35: 376-385
        • Tretiakova M.S.
        Eosinophilic solid and cystic renal cell carcinoma mimicking epithelioid angiomyolipoma: series of 4 primary tumors and 2 metastases.
        Hum Pathol. 2018; 80: 65-75
        • Trpkov K.
        • Abou-Ouf H.
        • Hes O.
        • et al.
        Eosinophilic solid and cystic renal cell carcinoma (ESC RCC): further morphologic and molecular characterization of ESC RCC as a distinct entity.
        Am J Surg Pathol. 2017; 41: 1299-1308
        • Trpkov K.
        • Hes O.
        • Bonert M.
        • et al.
        Eosinophilic, solid, and cystic renal cell carcinoma: clinicopathologic study of 16 unique, sporadic neoplasms occurring in women.
        Am J Surg Pathol. 2016; 40: 60-71
        • Amin M.B.
        • Crotty T.B.
        • Tickoo S.K.
        • et al.
        Renal oncocytoma: a reappraisal of morphologic features with clinicopathologic findings in 80 cases.
        Am J Surg Pathol. 1997; 21: 1-12
        • Al-Obaidy K.I.
        • Cheng L.
        Renal oncocytoma with adverse pathologic features: a clinical and pathologic study of 50 cases.
        Mod Pathol. 2021; 34: 1947-1954
        • Williamson S.R.
        • Gadde R.
        • Trpkov K.
        • et al.
        Diagnostic criteria for oncocytic renal neoplasms: a survey of urologic pathologists.
        Hum Pathol. 2017; 63: 149-156
        • Hes O.
        • Michal M.
        • Boudova L.
        • et al.
        Small cell variant of renal oncocytoma--a rare and misleading type of benign renal tumor.
        Int J Surg Pathol. 2001; 9: 215-222
        • Kuroda N.
        • Yorita K.
        • Naroda T.
        • et al.
        Renal oncocytoma, small cell variant, with pseudorosettes, showing cyclin D1 expression and tubulovesicular cristae of mitochondria.
        Pathol Int. 2016; 66: 409-410
        • Li K.
        • Wang C.
        • Xiong X.
        • et al.
        Small-cell variant renal oncocytoma: case report on its clinicopathological and genetic characteristics and literature review.
        Gene. 2020; 730: 144266
        • Magro G.
        • Gardiman M.P.
        • Lopes M.R.
        • et al.
        Small-cell variant of renal oncocytoma with dominating solid growth pattern: a potential diagnostic pitfall.
        Virchows Arch. 2006; 448: 379-380
        • Williamson S.R.
        Renal Oncocytoma With Perinephric Fat Invasion.
        Int J Surg Pathol. 2016; 24: 625-626
        • Wobker S.E.
        • Przybycin C.G.
        • Sircar K.
        • et al.
        Renal oncocytoma with vascular invasion: a series of 22 cases.
        Hum Pathol. 2016; 58: 1-6
        • Sukov W.R.
        • Ketterling R.P.
        • Lager D.J.
        • et al.
        CCND1 rearrangements and cyclin D1 overexpression in renal oncocytomas: frequency, clinicopathologic features, and utility in differentiation from chromophobe renal cell carcinoma.
        Hum Pathol. 2009; 40: 1296-1303
        • Trpkov K.
        • Hes O.
        • Williamson S.R.
        • et al.
        New developments in existing WHO entities and evolving molecular concepts: the genitourinary pathology society (GUPS) update on renal neoplasia.
        Mod Pathol. 2021; 34: 1392-1424
        • Ruiz-Cordero R.
        • Rao P.
        • Li L.
        • et al.
        Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma.
        Mod Pathol. 2019; 32: 1698-1707
        • Menko F.H.
        • van Steensel M.A.
        • Giraud S.
        • et al.
        Birt-Hogg-Dubé syndrome: diagnosis and management.
        Lancet Oncol. 2009; 10: 1199-1206
        • Schmidt L.S.
        • Linehan W.M.
        FLCN: The causative gene for Birt-Hogg-Dubé syndrome.
        Gene. 2018; 640: 28-42
        • Furuya M.
        • Hasumi H.
        • Yao M.
        • et al.
        Birt-Hogg-Dubé syndrome-associated renal cell carcinoma: Histopathological features and diagnostic conundrum.
        Cancer Sci. 2020; 111: 15-22
        • Pavlovich C.P.
        • Walther M.M.
        • Eyler R.A.
        • et al.
        Renal tumors in the Birt-Hogg-Dubé syndrome.
        Am J Surg Pathol. 2002; 26: 1542-1552
        • Napolitano G.
        • Di Malta C.
        • Esposito A.
        • et al.
        A substrate-specific mTORC1 pathway underlies Birt-Hogg-Dubé syndrome.
        Nature. 2020; 585: 597-602
        • Gupta S.
        • Swanson A.A.
        • Chen Y.B.
        • et al.
        Incidence of succinate dehydrogenase and fumarate hydratase-deficient renal cell carcinoma based on immunohistochemical screening with SDHA/SDHB and FH/2SC.
        Hum Pathol. 2019; 91: 114-122
        • Wang G.
        • Rao P.
        Succinate dehydrogenase-deficient renal cell carcinoma: a short review.
        Arch Pathol Lab Med. 2018; 142: 1284-1288
        • Fuchs T.L.
        • Maclean F.
        • Turchini J.
        • et al.
        Expanding the clinicopathological spectrum of succinate dehydrogenase-deficient renal cell carcinoma with a focus on variant morphologies: a study of 62 new tumors in 59 patients.
        Mod Pathol. 2022; 35: 836-849
        • Aggarwal R.K.
        • Luchtel R.A.
        • Machha V.
        • et al.
        Functional succinate dehydrogenase deficiency is a common adverse feature of clear cell renal cancer.
        Proc Natl Acad Sci U S A. 2021; 118 (e2106947118)
        • Williamson S.R.
        • Hornick J.L.
        • Eble J.N.
        • et al.
        Renal cell carcinoma with angioleiomyoma-like stroma and clear cell papillary renal cell carcinoma: exploring SDHB protein immunohistochemistry and the relationship to tuberous sclerosis complex.
        Hum Pathol. 2018; 75: 10-15
        • Mancilla-Jimenez R.
        • Stanley R.J.
        • Blath R.A.
        Papillary renal cell carcinoma: a clinical, radiologic, and pathologic study of 34 cases.
        Cancer. 1976; 38: 2469-2480
        • Li C.X.
        • Lu Q.
        • Huang B.J.
        • et al.
        Routine or enhanced imaging to differentiate between type 1 and type 2 papillary renal cell carcinoma.
        Clin Radiol. 2021; 76: 135-142
        • Magers M.J.
        • Perrino C.M.
        • Cramer H.M.
        • et al.
        Cytomorphologic comparison of type 1 and type 2 papillary renal cell carcinoma: a retrospective analysis of 28 cases.
        Cancer Cytopathol. 2019; 127: 370-376
        • Motoshima T.
        • Komohara Y.
        • Ma C.
        • et al.
        PD-L1 expression in papillary renal cell carcinoma.
        BMC Urol. 2017; 17: 8
        • Murugan P.
        • Jia L.
        • Dinatale R.G.
        • et al.
        Papillary renal cell carcinoma: a single institutional study of 199 cases addressing classification, clinicopathologic and molecular features, and treatment outcome.
        Mod Pathol. 2022; 35: 825-835
        • Ravaud A.
        • Oudard S.
        • De Fromont M.
        • et al.
        First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG).
        Ann Oncol. 2015; 26: 1123-1128
        • Ungari M.
        • Trombatore M.
        • Ferrero G.
        • et al.
        Eosinophilic cytoplasmic inclusions in type 2 papillary renal cell carcinoma.
        Pathologica. 2019; 111: 369-374
        • Warrick J.I.
        • Tsodikov A.
        • Kunju L.P.
        • et al.
        Papillary renal cell carcinoma revisited: a comprehensive histomorphologic study with outcome correlations.
        Hum Pathol. 2014; 45: 1139-1146
        • Wong E.C.L.
        • Di Lena R.
        • Breau R.H.
        • et al.
        Morphologic subtyping as a prognostic predictor for survival in papillary renal cell carcinoma: Type 1 vs. type 2.
        Urol Oncol. 2019; 37: 721-726
        • Williamson S.R.
        • Gill A.J.
        • Argani P.
        • et al.
        Report from the international society of urological pathology (ISUP) consultation conference on molecular pathology of urogenital cancers: III: molecular pathology of kidney cancer.
        Am J Surg Pathol. 2020; 44: e47-e65
        • Linehan W.M.
        • Spellman P.T.
        • Ricketts C.J.
        • et al.
        Comprehensive molecular characterization of papillary renal-cell carcinoma.
        N Engl J Med. 2016; 374: 135-145
        • Srigley J.R.
        • Delahunt B.
        • Eble J.N.
        • et al.
        The international society of urological pathology (ISUP) vancouver classification of renal neoplasia.
        Am J Surg Pathol. 2013; 37: 1469-1489
        • Al-Obaidy K.I.
        • Eble J.N.
        • Cheng L.
        • et al.
        Papillary renal neoplasm with reverse polarity: a morphologic, immunohistochemical, and molecular study.
        Am J Surg Pathol. 2019; 43: 1099-1111
        • Saleeb R.M.
        • Brimo F.
        • Farag M.
        • et al.
        Toward biological subtyping of papillary renal cell carcinoma with clinical implications through histologic, immunohistochemical, and molecular analysis.
        Am J Surg Pathol. 2017; 41: 1618-1629
        • Kunju L.P.
        • Wojno K.
        • Wolf Jr., J.S.
        • et al.
        Papillary renal cell carcinoma with oncocytic cells and nonoverlapping low grade nuclei: expanding the morphologic spectrum with emphasis on clinicopathologic, immunohistochemical and molecular features.
        Hum Pathol. 2008; 39: 96-101
        • Al-Obaidy K.I.
        • Eble J.N.
        • Nassiri M.
        • et al.
        Recurrent KRAS mutations in papillary renal neoplasm with reverse polarity.
        Mod Pathol. 2020; 33: 1157-1164
        • Wei S.
        • Kutikov A.
        • Patchefsky A.S.
        • et al.
        Papillary renal neoplasm with reverse polarity is often cystic: report of 7 cases and review of 93 cases in the literature.
        Am J Surg Pathol. 2022; 46: 336-343
        • Zhou L.
        • Xu J.
        • Wang S.
        • et al.
        Papillary renal neoplasm with reverse polarity: a clinicopathologic study of 7 cases.
        Int J Surg Pathol. 2020; 28: 728-734
        • Parwani A.V.
        • Husain A.N.
        • Epstein J.I.
        • et al.
        Low-grade myxoid renal epithelial neoplasms with distal nephron differentiation.
        Hum Pathol. 2001; 32: 506-512
        • Billis A.
        Phenotypic, molecular and ultrastructural studies of a novel low grade renal epithelial neoplasm possibly related to the loop of Henle.
        Int Braz J Urol. 2002; 28: 477-478
        • Fine S.W.
        • Argani P.
        • DeMarzo A.M.
        • et al.
        Expanding the histologic spectrum of mucinous tubular and spindle cell carcinoma of the kidney.
        Am J Surg Pathol. 2006; 30: 1554-1560
        • Yang C.
        • Cimera R.S.
        • Aryeequaye R.
        • et al.
        Adverse histology, homozygous loss of CDKN2A/B, and complex genomic alterations in locally advanced/metastatic renal mucinous tubular and spindle cell carcinoma.
        Mod Pathol. 2021; 34: 445-456
        • Ren Q.
        • Wang L.
        • Al-Ahmadie H.A.
        • et al.
        Distinct genomic copy number alterations distinguish mucinous tubular and spindle cell carcinoma of the kidney from papillary renal cell carcinoma with overlapping histologic features.
        Am J Surg Pathol. 2018; 42: 767-777
        • Wang L.
        • Zhang Y.
        • Chen Y.B.
        • et al.
        VSTM2A overexpression is a sensitive and specific biomarker for mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney.
        Am J Surg Pathol. 2018; 42: 1571-1584
        • Lau H.D.
        • Chan E.
        • Fan A.C.
        • et al.
        A clinicopathologic and molecular analysis of fumarate hydratase-deficient renal cell carcinoma in 32 patients.
        Am J Surg Pathol. 2020; 44: 98-110
        • Buelow B.
        • Cohen J.
        • Nagymanyoki Z.
        • et al.
        Immunohistochemistry for 2-succinocysteine (2SC) and fumarate hydratase (FH) in cutaneous leiomyomas may aid in identification of patients With HLRCC (Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome).
        Am J Surg Pathol. 2016; 40: 982-988
        • Ezekian B.
        • Englum B.
        • Gilmore B.F.
        • et al.
        Renal medullary carcinoma: a national analysis of 159 patients.
        Pediatr Blood Cancer. 2017; 64: e26609
        • Baniak N.
        • Tsai H.
        • Hirsch M.S.
        The differential diagnosis of medullary-based renal masses.
        Arch Pathol Lab Med. 2021; 145: 1148-1170
        • Calderaro J.
        • Moroch J.
        • Pierron G.
        • et al.
        SMARCB1/INI1 inactivation in renal medullary carcinoma.
        Histopathology. 2012; 61: 428-435
        • Jia L.
        • Carlo M.I.
        • Khan H.
        • et al.
        Distinctive mechanisms underlie the loss of SMARCB1 protein expression in renal medullary carcinoma: morphologic and molecular analysis of 20 cases.
        Mod Pathol. 2019; 32: 1329-1343
        • Bratslavsky G.
        • Gleicher S.
        • Jacob J.M.
        • et al.
        Comprehensive genomic profiling of metastatic collecting duct carcinoma, renal medullary carcinoma, and clear cell renal cell carcinoma.
        Urol Oncol. 2021; 39: 367.e361-367.e365